References
American Academy of Pediatrics. (2012). HPV vaccine recommendations. Pediatrics, 129 (3), 602 – 605. doi:10.1542/peds.2011-3865
American Nurses Association. (2015a). Code of ethics for nurses with interpretive statements : Silver Spring, Maryland: ANA, American Nurses Association.
American Nurses Association. (2015b). Position statement on immunizations. Retrieved from https://www.nursingworld.org/practice-policy/nursing-excellence/official-position- statements/id/immunizations/
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev, 5 , Cd009069. doi:10.1002/14651858.CD009069.pub3
Bailey, H. H., Chuang, L. T., duPont, N. C., Eng, C., Foxhall, L. E., Merrill, J. K., . . . Blanke, C. D. (2016). American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. Journal of Clinical Oncology, 34 (15), 1803-1812. doi:10.1200/JCO.2016.67.2014 Brisson, M., Laprise, J. F., Drolet, M., Van de Velde, N., Franco, E. L., Kliewer, E. V., . . . Boily, M. C. (2013). Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine, 31 (37), 3863-3871. doi:10.1016/j.vaccine.2013.06.064
Castle, P. E., & Maza, M. (2015). Prophylactic HPV vaccination: past, present, and future. Epidemiology and Infection , 1-20. doi:10.1017/S0950268815002198
Centers for Disease Control and Prevention. (2016). Vaccines for Children Program. Retrieved from https://www.cdc.gov/vaccines/programs/vfc/index.html
Chesson, H. W., Ekwueme, D. U., Saraiya, M., Watson, M., Lowy, D. R., & Markowitz, L. E. (2012). Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine, 30 (42), 6016-6019. doi:10.1016/j.vaccine.2012.07.056 Chesson, H. W., Markowitz, L. E., Hariri, S., Ekwueme, D. U., & Saraiya, M. (2016). The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model. Human Vaccines & Immunotherapeutics, 12 (6), 1363-1372. doi:10.1080/21645515.2016.1140288
Powered by FlippingBook